Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pelvic Cancer Clear all
Active, not recruiting Phase 2 Interventional

A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer

NCT04190446
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
Radiation · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 22, 2026, 12:24 PM EDT
Recruiting Early Phase 1 Interventional

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

NCT05691010
View directory record Official record
Conditions
Endometrial Cancer, Stage III Endometrial Cancer, Stage III Endometrial Carcinoma, Endometrial Carcinoma, Endometrial Carcinoma Stage III
Interventions
Intensity-modulated radiation therapy, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 12:24 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

NCT05603910
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma
Interventions
Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Aaron Wolfson
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HIPEC After Radical Cystectomy for High Risk Bladder Cancer

NCT03514888
View directory record Official record
Conditions
Invasive Bladder Cancer
Interventions
HIPEC
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Jul 22, 2026, 12:24 PM EDT
Recruiting Phase 3 Interventional

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

NCT06915727
View directory record Official record
Conditions
Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm, Malignant Abdominal Neoplasm, Malignant Neck Neoplasm, Malignant Pelvic Neoplasm, Metastatic Childhood Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Near Infrared Imaging, Pafolacianine Sodium, Surgical Procedure
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Months to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Phase 3 Interventional

Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer

NCT00022191
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
cisplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
58
States / cities
Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

NCT01846520
View directory record Official record
Conditions
Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Psychosocial Effects of Cancer and Its Treatment, Recurrent Bladder Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Uterine Sarcoma, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage II Bladder Cancer, Stage II Renal Cell Cancer, Stage II Urethral Cancer, Stage IIA Cervical Cancer, Stage IIA Colon Cancer, Stage IIA Gastric Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIA Uterine Sarcoma, Stage IIB Cervical Cancer, Stage IIB Colon Cancer, Stage IIB Gastric Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIB Uterine Sarcoma, Stage IIC Colon Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage IIC Rectal Cancer, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage III Urethral Cancer, Stage IIIA Cervical Cancer, Stage IIIA Colon Cancer, Stage IIIA Gastric Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Rectal Cancer, Stage IIIA Uterine Sarcoma, Stage IIIB Cervical Cancer, Stage IIIB Colon Cancer, Stage IIIB Gastric Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Rectal Cancer, Stage IIIB Uterine Sarcoma, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Rectal Cancer, Stage IIIC Uterine Sarcoma, Stage IV Bladder Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IV Urethral Cancer, Stage IVA Cervical Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Uterine Sarcoma, Stage IVB Cervical Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Stage IVB Uterine Sarcoma, Ureter Cancer, Stage IIA Lung Carcinoma, Stage IIB Lung Carcinoma, Stage IIIA Lung Carcinoma, Stage IIIB Lung Carcinoma
Interventions
educational intervention, telephone-based intervention, quality-of-life assessment, questionnaire administration
Other · Behavioral · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Phase 4 Interventional

The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.

NCT00995878
View directory record Official record
Conditions
Symptomatic Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Interventions
Focused ultrasound (MRgFUS), Uterine artery embolization (UAE)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jul 22, 2026, 12:24 PM EDT
Active, not recruiting Not applicable Interventional

A Study of Near-Infrared Fluorescence Imaging With ICG During Reconstructive Gynecologic Surgery

NCT05071976
View directory record Official record
Conditions
Gynecologic Surgery
Interventions
ICG-NIR angiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 22, 2026, 12:24 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

NCT01234519
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
AEZS-108, AEZS-108 at MTD
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Miami, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Phase 1 Interventional

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

NCT00186953
View directory record Official record
Conditions
Abdominal Neoplasms, Pelvic Neoplasms
Interventions
Optison
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 20 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Jul 22, 2026, 12:24 PM EDT
Recruiting Phase 2 Interventional

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

NCT05756569
View directory record Official record
Conditions
Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm, Malignant Urethral Neoplasm, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Unresectable Bladder Carcinoma, Urachal Adenocarcinoma, Bladder Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jul 22, 2026, 12:24 PM EDT
Recruiting Not applicable Interventional

Vaginal Dilator Therapy After Pelvic Radiation

NCT07216456
View directory record Official record
Conditions
Pelvic Radiotherapy, Vaginal Stenosis, Pelvic Cancer, Gynecologic Cancers, Anorectal Cancer, Urologic Cancer
Interventions
Improving Engagement with Vaginal Dilator Therapy after Pelvic Radiation
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 12:24 PM EDT
Terminated Phase 2 Interventional

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

NCT00004856
View directory record Official record
Conditions
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
trastuzumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Jul 22, 2026, 12:24 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

NCT05100472
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation
Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 22, 2026, 12:24 PM EDT
Not yet recruiting Phase 2 Interventional

GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries

NCT07415681
View directory record Official record
Conditions
Gynaecologic Cancer, Cervical Cancer, Radiation Therapy
Interventions
Volume Modulated Arc Therapy (VMAT), Intensity Modulated Proton Therapy (IMPT)
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Prehabilitation for Pelvic Cancer: Changes in Setup Variability

NCT03242538
View directory record Official record
Conditions
Pelvic Cancer
Interventions
Pelvic Exercise
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Not applicable Interventional Results available

Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis

NCT01757717
View directory record Official record
Conditions
Metastatic or Recurrent Lesions in the Spine, Metastatic or Recurrent Lesions in the Pelvis
Interventions
Ir-192 high dose rate (HDR)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery

NCT00331760
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer
Interventions
cisplatin, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
151
States / cities
Auburn, California • Cameron Park, California • Carmichael, California + 103 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 22, 2026, 12:24 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer

NCT00003379
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, paclitaxel, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
31
States / cities
Phoenix, Arizona • Newark, Delaware • Chicago, Illinois + 26 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Jul 22, 2026, 12:24 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT03606174
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions
Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
36
States / cities
Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Jul 22, 2026, 12:24 PM EDT
Completed Phase 1 Interventional

Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer

NCT00068549
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions
Gemcitabine Hydrochloride, Cisplatin, Radiation Therapy, Internal Radiation Therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Jul 22, 2026, 12:24 PM EDT